Observational Study to Evaluate the Efficacy of OLMETEC Tab on Nocturnal Blood Pressure Control in Patients With Stage Ⅰ Hypertension

This is a prospective, multicenter, observational study designed to evaluate the effectiveness of Olmetec® (olmesartan medoxomil) or Olmetec Plus® (olmesartan medoxomil/hydrochlorothiazide) on nocturnal blood pressure control in Korean patients with stage 1 hypertension.

In routine clinical practice, patients diagnosed with stage 1 hypertension and newly prescribed Olmetec® or Olmetec Plus® according to the approved label and the physician's clinical judgment will be enrolled and followed prospectively. No additional intervention beyond standard medical care will be applied.

Ambulatory blood pressure monitoring (ABPM) will be used to assess 24-hour blood pressure profiles, including nocturnal blood pressure, daytime blood pressure, and blood pressure variability. Measurements will be performed at baseline and after treatment to evaluate changes over time.

The primary objective of this study is to assess the change in mean systolic blood pressure from baseline to 12 weeks (up to 20 weeks). Secondary objectives include evaluation of diastolic blood pressure, nocturnal blood pressure, blood pressure variability, responder rate, and changes in dipping patterns. Safety will be assessed by monitoring adverse events during the study period.

This study aims to generate real-world evidence on the effectiveness and safety of Olmetec-based therapy in controlling nocturnal blood pressure and improving blood pressure variability in patients with stage 1 hypertension.

Primary outcomes

• Change in mean 24-hour systolic blood pressure [Baseline to 12 weeks (up to 20 weeks)]: Change in mean 24-hour systolic blood pressure measured by ambulatory blood pressure monitoring (ABPM) from baseline to 12 weeks (up to 20 weeks).

Secondary outcomes

• Change in clinic systolic and diastolic blood pressure [Baseline to 12 weeks (up to 20 weeks)]: Change in clinic systolic and diastolic blood pressure from baseline.
• Responder rate [At 12 weeks (up to 20 weeks)]: Proportion of patients achieving systolic blood pressure <140 mmHg or a reduction of ≥20 mmHg from baseline.
• Change in mean 24-hour diastolic blood pressure [Baseline to 12 weeks (up to 20 weeks)]
• Change in nocturnal systolic and diastolic blood pressure [Baseline to 12 weeks (up to 20 weeks)]
• Change in daytime systolic and diastolic blood pressure [Baseline to 12 weeks (up to 20 weeks)]
• Change in blood pressure variability [Baseline to 12 weeks (up to 20 weeks)]: Change in variability indices of 24-hour, daytime, and nocturnal blood pressure.
• Change in dipping status (dipper/non-dipper proportion) [Baseline to 12 weeks (up to 20 weeks)]
• Dipper conversion rate [At 12 weeks (up to 20 weeks)]
• Change in morning blood pressure surge (MBPS) [Baseline to 12 weeks (up to 20 weeks)]
• Change in pulse pressure [Baseline to 12 weeks (up to 20 weeks)]

Sex: All, ages: 19 Years to any

Inclusion Criteria:

* Adults aged ≥19 years
* Patients diagnosed with stage 1 hypertension according to clinical guidelines
* Patients who are newly prescribed Olmetec® or Olmetec Plus® in routine -clinical practice
* Patients who are able to undergo ambulatory blood pressure monitoring (ABPM)
* Patients who voluntarily agree to participate and provide written informed consent

Exclusion Criteria:

* Patients with secondary hypertension
* Patients with severe hypertension requiring immediate pharmacological i-ntervention
* Patients with known hypersensitivity to olmesartan medoxomil, hydrochlorothiazide, or any component of the study drugs
* Patients who are pregnant, planning to become pregnant, or breastfeeding
* Patients with severe renal impairment or severe hepatic impairment
* Patients who are unable to comply with study procedures, including ABPM
* Patients who are deemed inappropriate for participation by the investigator